Patenting and Pricing Eliquis, Ozempic, and Other Medicare-Targeted Drugs

Teddy Downey, Executive Editor of The Capitol Forum, sits down with Tahir Amin, co-founder of I-MAK, to discuss the pharmaceutical industry’s misuse of the U.S. patent system—and what it costs American patients and taxpayers.

They dive into I-MAK’s new report, Overpatented, Overpriced, and explore:

• How drugs like Eliquis and Ozempic are protected by dozens to hundreds of patents
• The role of patent term extensions, follow-on patents, and settlement deals in delaying generic competition
• How companies like Novo Nordisk and BMS generate tens of billions in additional revenue through strategic patenting
• Why the Hatch-Waxman Act and USPTO are failing to protect patients and the public interest

Prefer audio? Listen to the full discussion on drug patenting and pricing.